Ozempic is the hot drug for weight loss, but its original purpose was to help diabetics – putting its creator in a bit of a bind. Wired contributor Virginia Heffernan joins host Krys Boyd to discuss how Danish drugmaker Novo Nordisk is stretched thin as demand for the drug skyrockets – and how President Trump’s designs on Greenland might actually affect supply. Her article is “The King of Ozempic Is Scared as Hell.” Learn about your ad choices: dovetail.prx.org/ad-choices